Targets › ATM
6 programs from 6 companies in 16 trials: 15 Phase 1, 1 Phase 2; Oncology, Neurology; next expected readout Dec 2026.
Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism (By similarity). (UniProt, Q13315)
Open in Phaseline: the race on ATM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| David Reardon, MD | CC-115 mTOR and ATM kinase inhibitor | MTOR, ATM | Phase 2 | Glioblastoma | Feb 2028 |
| National Cancer Institute (NCI) | Peposertib DNA-PKcs inhibitor | PRKDC, ATM | Phase 1 | Advanced Head and Neck Squamous Cell Carcinoma; Neuroendocrine Neoplasm; Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Dedifferentiated Liposarcoma … | Dec 2026 |
| Exelixis | XL309 (ISM3091) ATM inhibitor | ATM | Phase 1 | Advanced Solid Tumor | Apr 2027 |
| Children's Oncology Group | AZD1390 ATM kinase inhibitor | ATM | Phase 1 | Childhood Astrocytoma | Mar 2028 |
| Timothy Yu | Atipeksen Splice-switching antisense oligonucleotide targeting ATM c.7865C>T mutation to restore nor | ATM | Phase 1 | Ataxia Telangiectasia | Dec 2032 |
| AstraZeneca | AZD1390 ATM inhibitor | ATM | Phase 1 | Recurrent Glioblastoma Multiforme; Non Small Cell Lung Cancer; Solid Tumor | – |
Advanced Head and Neck Squamous Cell Carcinoma (1) Neuroendocrine Neoplasm (1) Metastatic Castration-Resistant Prostate Carcinoma (1) Metastatic Dedifferentiated Liposarcoma (1) Endometrial High Grade Endometrioid Adenocarcinoma (1) Recurrent Acute Myeloid Leukemia (1) Locally Advanced Malignant Solid Neoplasm (1) Locally Advanced Pancreatic Adenocarcinoma (1) Advanced Malignant Solid Neoplasm (1) Ataxia Telangiectasia (1) Childhood Astrocytoma (1) Glioblastoma (1)
small molecule (3), mixed (1), other (1), protein or peptide (1)
National Cancer Institute (NCI) (1) Timothy Yu (1) Children's Oncology Group (1) David Reardon, MD (1) Exelixis (1) AstraZeneca (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.